ANGLE plc collaborates with AstraZeneca on cutting-edge cancer detection technology
ANGLE plc, a leading innovator in liquid biopsy and circulating tumour cell (CTC) solutions, has announced a significant supplier agreement with global biopharmaceutical leader AstraZeneca PLC. The collaboration focuses on developing a novel methodology for the detection of micronuclei in CTCs, utilizing ANGLE’s DNA damage response (DDR) assay, a key marker in cancer diagnostics and […]